Treace Medical reports Q3 adjusted EPS (22c), consensus (29c)

Reports Q3 revenue $33.06M, consensus $30.07M. "We are pleased with the continued momentum of our business as revenue increased 53% in the third quarter and 51% for the first nine months of 2022. Our strong results benefited from our strategic investments in the industry’s only bunion-focused direct sales channel, targeted R&D initiatives and direct-to-consumer programs which we believe continues to position us for sustained growth as we scale our operations," said John Treace, CEO, founder and Board Member of Treace.